Incyte Corp
NASDAQ:INCY
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Incyte Corp
Total Receivables
Incyte Corp
Total Receivables Peer Comparison
Competitive Total Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Incyte Corp
NASDAQ:INCY
|
Total Receivables
$745.5m
|
CAGR 3-Years
23%
|
CAGR 5-Years
25%
|
CAGR 10-Years
32%
|
|
Abbvie Inc
NYSE:ABBV
|
Total Receivables
$11.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
16%
|
CAGR 10-Years
10%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Receivables
$4.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Receivables
$6.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Receivables
$1.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
33%
|
CAGR 10-Years
40%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Receivables
$5.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
18%
|
CAGR 10-Years
17%
|
See Also
What is Incyte Corp's Total Receivables?
Total Receivables
745.5m
USD
Based on the financial report for Mar 31, 2024, Incyte Corp's Total Receivables amounts to 745.5m USD.
What is Incyte Corp's Total Receivables growth rate?
Total Receivables CAGR 10Y
32%
Over the last year, the Total Receivables growth was 20%. The average annual Total Receivables growth rates for Incyte Corp have been 23% over the past three years , 25% over the past five years , and 32% over the past ten years .